Programme SOM0044 for Parkinson’s Disease
SOM0044 is a small molecule for the treatment of Parkinson’s disease.
Beovu® (Brolucizumab) for the Treatment of wet Age-related Macular Degeneration (AMD)
Brolucizumab was approved based on the outcome of HAWK and HARRIER phase three studies. Credit: Novartis.
Learn more
Hover over the logos to learn more about the companies who made this project possible.
Close
-
Noble Life Sciences
Noble Life Sciences is a contract research organisation (CRO) offering...
About
Noble Life Sciences is a contract research organisation (CRO) offering preclinical development solutions for drugs, vaccines and medical devices.
FollowMake an Enquiry
-
esqLABS
Founded in 2017, esqLABS provides platform technologies, software, consulting and...
About
Founded in 2017, esqLABS provides platform technologies, software, consulting and workshops for data analysis and model-based decision support throughout the healthcare industry.
FollowMake an Enquiry
-
SOM Biotech
SOM Biotech is an Artificial Intelligence AI drug discovery and...
About
SOM Biotech is an Artificial Intelligence AI drug discovery and development company focused on the development of therapies for orphan indications through the proprietary AI-based drug discovery technology.
FollowMake an Enquiry
